Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma
Lauren Jia-Yi Li, Andreana Yang Leow, Joyce Chi, Maggie Yuxi Zhou, Nam Bui, Allison Pribnow, Kristen Ganjoo, Minggui Pan
Springer Nature ·
2026-11-12
· DOI 10.1038/s44276-026-00257-3
⬢ Цитируемость: 0Crossref
Аннотация
BJC Reports, Published online: 12 November 2026; doi:10.1038/s44276-026-00257-3 Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma
Lauren Jia-Yi Li, Andreana Yang Leow, Joyce Chi, Maggie Yuxi Zhou, Nam Bui, Allison Pribnow et al. Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma. // BJC Reports. – 2026. – DOI: 10.1038/s44276-026-00257-3. – URL: https://www.nature.com/articles/s44276-026-00257-3
Lauren Jia-Yi Li, Andreana Yang Leow, Joyce Chi, Maggie Yuxi Zhou, Nam Bui, Allison Pribnow, Kristen Ganjoo, & Minggui Pan (2026). Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma. BJC Reports. https://doi.org/10.1038/s44276-026-00257-3
Lauren Jia-Yi Li, et al. “Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma.” BJC Reports, 2026. doi:10.1038/s44276-026-00257-3.
@article{Li2026,
title = {Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma},
author = {Li, Lauren Jia-Yi and Leow, Andreana Yang and Chi, Joyce and Zhou, Maggie Yuxi and Bui, Nam and Pribnow, Allison and Ganjoo, Kristen and Pan, Minggui},
journal = {BJC Reports},
year = {2026},
doi = {10.1038/s44276-026-00257-3},
url = {https://www.nature.com/articles/s44276-026-00257-3}
}